



Contents lists available at [ScienceDirect](#)

Indian Heart Journal

journal homepage: www.elsevier.com/locate/ihj



Review Article

Angiotensin-converting enzyme inhibitors and receptor blockers in heart failure and chronic kidney disease – Demystifying controversies

Kader Muneer*, Anishkumar Nair

Department of Cardiology, Government Medical College, Kozhikode, Kerala, India

ARTICLE INFO

Article history:

Received 28 February 2016

Accepted 14 August 2016

Available online xxx

Keywords:

Congestive heart failure

Chronic kidney disease

ACE inhibitors

Angiotensin receptor blockers

Creatinine

ABSTRACT

In clinical setting, congestive heart failure (CHF) and chronic kidney disease (CKD) often co-exist in patients due to common underlying predisposing factors. An intricate equilibrium between the cardiovascular and renal system is maintained through rennin angiotensin–aldosterone axis and autonomic nervous system. Consequent to favorable hemodynamic modification, angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blocking (ARB) therapy have proven to be an indispensable aspect of heart failure management with morbidity and mortality benefit. Additionally, progression to end stage renal failure may be halted by renin angiotensin aldosterone system (RAAS) blockade in patients with preexisting renal dysfunction. However, concern over the safety of RAAS blockade in presence of renal impairment has led to profound underutilization of these drugs in CHF patients with renal insufficiency. This review aims to provide a simplified guide to pathophysiology and management options of this perplexing situation.

© 2016 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Queries abound on the management strategy to follow when chronic kidney disease and heart failure co-exist in a patient. Among treatment options available, most perplexing question is whether to initiate or continue renin angiotensin aldosterone blocking agents in such patients. Despite of beneficial cardio-renal interactions of these medications, an apprehension over possible renal worsening often leads to its underuse in clinical practice. Through this review, we hope to outline guideline based simplified management strategy in such cases.

Renal insufficiency management is a significant aspect of heart failure (HF) treatment not only because of its high prevalence consequent to shared risk factors, but also its association with mortality.¹ Major randomized trials have shown that ACEI and/or ARB in addition to standard cardiac medications have survival benefit in HF patients.² However, under representation of coexistent renal insufficiency in HF trials has led to skewed data and failure to generalize these results among patients having concomitant kidney disease.³ Moreover chronic kidney disease

(CKD) patients are frequently refractory to conventional treatment and are at increased risk of adverse effects with HF medications.⁴

Serum creatinine (sCr) level despite being an insensitive measure of glomerular filtration rate (GFR), it is often the favored parameter to assess the renal impairment in clinical practice. It has a nonlinear association with GFR, which varies with age, sex and body mass. To overcome these limitations, estimated glomerular filtration rate (eGFR) estimated by Cockcroft–Gault equation is now considered ideal for assessing renal function. Renal insufficiency is diagnosed with eGFR <90 ml/min/1.7 m² and various stages categorized depending on eGFR values. Chronic kidney disease is defined as eGFR <60 ml/min/1.73 m² for ≥3 months, with or without kidney damage.⁵

2. Pathophysiology

HF is a multifaceted syndrome that is consequent to any structural or functional impediment in ventricular filling or ejection of blood.⁶ It is diagnosed clinically based on manifestations secondary to congestion of systemic and/or pulmonary venous systems. HF classification based on left ventricular ejection fraction has prognostic and therapeutic importance. Even in presence of normal ejection fraction, excess volume overload consequent to renal dysfunction may result in clinical features of heart failure.⁷ Moreover assessment of cardiac failure is difficult in volume overloaded patients with renal dysfunction. Ventricular

* Corresponding author at: Department of Cardiology, Government Medical College, Kozhikode, Kerala 673008, India.
E-mail address: drkm66@gmail.com (K. Muneer).

<http://dx.doi.org/10.1016/j.ihj.2016.08.007>

0019-4832/© 2016 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).




Fig. 1. Pathophysiologic pathways of RAAS interaction between heart failure and renal dysfunction. CHF – congestive heart failure, CKD – chronic kidney disease, RAAS – renin angiotensin aldosterone system, ACEi – angiotensin converting enzyme inhibitors, ARB – angiotensin receptor blocker, PAI-1 – plasminogen activator inhibitor-1, CVP – central venous pressure.

hypertrophy, diastolic dysfunction, pressure and volume overload in patients with CKD may contribute to the appearance or worsening of HF in patients with left ventricular dysfunction.⁸ Clinical manifestation of congestive heart failure (CHF) is present in approximately 20% of ESRD patients.⁹ Additionally, hemodynamic alteration produced by cardiac dysfunction may lead to worsening of renal function as adequate mean arterial pressure is necessary to maintain renal perfusion and glomerular filtration. Balance between the cardiovascular and renal system is maintained by an intricate link mediated through renin angiotensin-aldosterone axis and autonomic nervous system¹⁰ (Fig. 1).

3. Angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB)

ACEi and ARB are one of the most preferred therapeutic agents for management of hypertension. Their favorable hemodynamic alteration includes reduction of cardiac preload, afterload and systolic ventricular wall stress resulting in augmented cardiac output without proportionate increase in oxygen consumption.¹¹ This hemodynamic alteration maintains glomerular filtration by improving the renal perfusion and promoting sodium excretion. Hence they are instrumental in long term management of patients with hypertension, CHF, diabetic and non-diabetic nephropathy providing mortality benefit.¹² By preventing degradation of bradykinin, ACEi may improve organ perfusion enhancing kinin induced peripheral vasodilatation. But occasionally these drugs may result in mild renal insufficiency consequent to reduction in GFR. This functional renal insufficiency often occurs when renal perfusion is reduced secondary to decline in mean arterial pressure or when the GFR is highly angiotensin II dependent as in conditions like volume depletion, bilateral renal artery stenosis or renal artery stenosis in a single functional kidney as in transplant recipient.¹³ Although there is no creatinine value at which initiation of ACEi is contraindicated, it is advisable to be cautious while initiation of these medications when serum potassium is >5.5 mEq/L or systolic blood pressure is <90 mmHg. Usually ACEi and ARB associated renal insufficiency is transient and reversible with discontinuation of drugs.¹⁴

4. Renal hemodynamics in CHF

Renal blood flow and GFR are maintained over a wide range of mean arterial pressure by angiotensin II and sympathetic nervous system mediated renal auto-regulation.¹⁰ When renal perfusion pressure falls as in case of CHF, there is increased production of renin from juxtaglomerular cells and subsequent angiotensin II production. This leads to vasoconstriction of post-glomerular efferent arterioles and consequently glomerular capillary pressure increases. Angiotensin also increases distal convoluted tubule sodium reabsorption through aldosterone secretion. Thirst center activation along with free water absorption by ADH secretion helps to maintain intravascular volume. As a result, GFR is maintained despite reduction in mean arterial pressure.

RAAS blockade leads to reduction in systemic vascular resistance, sodium reabsorption, aldosterone and ADH secretion.¹¹ These beneficial effects of ACEi and ARB in patients with CHF is also associated with fall in GFR due to preferential dilatation of post-glomerular efferent arterioles resulting in reduction in filtration pressure. In a normotensive patient, this leads to mild (usually <20%) increase in serum creatinine. But in patients with MAP is less than 60 mm of Hg, diuretic induced hypovolemia or those with significant renal arterial disease, use of ACEi and ARB can lead to marked reduction in glomerular filtration pressure and acute worsening in renal function leading to acute renal failure (ARF).¹³ In CONCORD II trial (Cooperative North Scandinavian Enalapril Survival Study II) there is 2.4% incidence of acute renal dysfunction¹⁵ and in SOLVD trial (Studies of Left Ventricular Dysfunction) there is 4% relative likelihood of developing ARF with use of ACEi and ARB.¹⁶ ACE inhibitors and ARBs can be used as alternatives of each other, if the preferred class cannot be used and should be gradually titrated to maximum tolerated dose. Concept of increased inhibition of the renin system to improve heart failure outcomes was marred with hurdles. There are conflicting reports about use of combination of ACEi and ARB in heart failure patients. While trials like ONTARGET and ValHeFT showed no clinical benefit of such combination, others trials like CHARM- Added showed decreased hospitalization.¹⁷⁻¹⁹ However, the important point to note in these trials are remarkably low proportion of

Download English Version:

<https://daneshyari.com/en/article/5603773>

Download Persian Version:

<https://daneshyari.com/article/5603773>

[Daneshyari.com](https://daneshyari.com)